NCT05718544View on ClinicalTrials.gov

Mini-dose Esketamine-dexmedetomidine Supplemented Analgesia and Long-term Outcomes

PHASE4CompletedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

September 7, 2023

Study Completion Date

September 7, 2023

Conditions
Scoliosis CorrectionPostoperative AnalgesiaEsketamineDexmedetomidineChronic Postsurgical Pain
Interventions
DRUG

Esketamine

Esketamine 50 mg is included in the mixture for patient-controlled analgesia.

DRUG

Dexmedetomidine

Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.

DRUG

Sufentanil

Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER